



Bristol-Myers Squibb Company

December 21, 2007

Expedited Review Requested

NMSB2

Thomas K. Thompson
Nuclear Regulatory Commission
Region I
Commercial and R&D Branch
Division of Nuclear Materials Safety
475 Allendale Road
King of Prussia, PA 19406-1415

2007 DEC 26 AM 10:30

RECEIVED
REGION 1

03034187

Re: License Number 52-25361-01MD

Dear Mr. Thompson:

We are writing to inform the Nuclear Regulatory Commission of a pending transaction involving the holder of the above-referenced license, Bristol-Myers Squibb Radiopharmaceuticals, Inc. On December 17, 2007, Bristol-Myers Squibb Company (BMS) and Avista Capital Partners (Avista) reached an agreement under which Avista will acquire full ownership of Bristol-Myers Squibb Radiopharmaceuticals, Inc. (BMS Radiopharmaceuticals). BMS Radiopharmaceuticals is wholly owned by Bristol-Myers Squibb Pharma Company and E.R. Squibb & Sons, LLC. Bristol-Myers Squibb Pharma Company is a wholly owned subsidiary of E.R. Squibb & Sons, LLC, which is a wholly owned subsidiary of BMS. In accordance with Guidance About Changes of Control and About Bankruptcy Involving Byproduct, Source, or Special Nuclear Materials Licenses (NUREG-1556, Vol. 15, Appendix F), we respectfully submit the following information:

Question 1. *Provide a complete description of the transaction (transfer of stocks or assets, or merger). Indicate whether the name has changed and include the new name. Include the name and telephone number of a licensee contact who NRC may contact if more information is needed.*

The name of the licensed organization is Bristol-Myers Squibb Radiopharmaceuticals, Inc., with offices located at 361 San Francisco Street, Penthouse San Juan, Puerto Rico 00901. The two radiopharmacy locations covered by the license are 2525 Ave. Eduardo Ruberte, Coliseo Shopping Center, Office # 115, Ponce, Puerto Rico; and 150 Federico Costa Street, Suite #1, San Juan, Puerto Rico. The transaction involves the transfer of 100% of the stock of BMS Radiopharmaceuticals to a newly formed subsidiary of Avista, ACP Lantern Acquisition Inc. BMS Radiopharmaceuticals was incorporated in Puerto Rico in 2001, and will remain in existence with a new corporate name following the stock sale. The new corporate name has not yet been selected. However, for purposes of this notice, the licensee following completion of the transaction is referred to as "ACP Radiopharmaceuticals." The closing date for the transaction is tentatively scheduled for January 8, 2008.

141474

Question 2. *Describe any changes in personnel or duties that relate to the licensed program. Include training and experience for new personnel.*

The contact information will remain unchanged: Rolando Garcia is the Radiation Safety Officer at both radiopharmacies, and his telephone numbers are 787-842-5788 and 787-765-1571. An additional contact is Joel Cordero, Associate Director, Medical Imaging, Puerto Rico Operations ((787) 565-5598).

Question 3. *Describe any changes in the organization, location, facilities, equipment or procedures that relate to the licensed program.*

Upon completion of the transaction, none of the personnel named in the licenses will change. The only changes will involve some of the officers and directors of the licensee, and none of those individuals will have access to the byproduct materials covered by the license. None of the facilities, equipment, procedures or personnel involved in the day-to-day operations at the radiopharmacies will change as a result of the transaction. In particular, the current radiation safety officer will continue in place. There will be no changes in the use, possession, or storage of licensed materials or any changes in operating or emergency procedures as a result of the transaction.

Question 4. *Describe the status of the surveillance program (surveys, wipe tests, quality control) at the present time and the expected status at the time that control is to be transferred.*

All surveillance items and records, including radioactive material inventory, are current and will be current as of the closing date. The surveillance items and records will remain in the possession of ACP Radiopharmaceuticals following the closing.

Question 5. *Confirm that all records concerning the safe and effective decommissioning of the facility will be transferred to the transferee or to NRC, as appropriate. These records include documentation of surveys of ambient radiation levels and fixed and/or removable contamination, including methods and sensitivity.*

No changes regarding current operations are anticipated, and the transaction will not trigger any immediate decontamination and decommissioning ("D&D") obligations. ACP Radiopharmaceuticals will remain liable for D&D at the end of the useful life of the radiopharmacies or termination of the license. Any records concerning the safe and effective decommissioning of the facilities will remain in the possession of ACP Radiopharmaceuticals following the completion of the transfer.

Question 6. *Confirm that the transferee will abide by all constraints, conditions, requirements and commitments of the transferor or that the transferee will submit a complete description of the proposed licensed program.*


ACP Radiopharmaceuticals will continue to abide by all constraints, license conditions, requirements, representations, and commitments made to the NRC, as set forth in the

license. By their respective signatures set forth below, Bristol-Myers Squibb Company and ACP Lantern Acquisition Inc. acknowledge the transfer of the responsibilities set forth herein.


Please do not hesitate to contact Rolando Garcia or Joel Cordero in the event you have any questions or comments regarding the licensed facility. In the event you have any questions or comments regarding the proposed transaction, please contact John B. O'Loughlin, Jr., of Weil, Gotshal & Manges LLP, at 202-682-7050.

Thank you for your assistance and prompt review of this request.


Respectfully submitted:



Bristol-Myers Squibb Company (Seller)
by: Susan G. Voigt
Vice President, EHS and Corporate Product Quality
Route 206 & Province Line Road
Princeton, NJ 08543



Bristol-Myers Squibb Radiopharmaceuticals, Inc. (Licensee)
by: Edward Dwyer, Vice President and Treasurer
Route 206 & Province Line Road
Princeton, NJ 08543



ACP Lantern Acquisition, Inc. (Buyer)
by: BEVIN O'NEIL
c/o Avista Capital Holdings, LP
65 East 55th Street, 18th Floor
New York, NY 10022